HAEMATO AG Stock

Equities

HAEK

DE000A289VV1

Pharmaceuticals

End-of-day quote Hanseatische Wertpapierboerse Hamburg 06:00:00 2024-06-05 pm EDT 5-day change 1st Jan Change
17.5 EUR -5.41% Intraday chart for HAEMATO AG -1.13% 0.00%
1 week-1.13%
Current month-4.37%
Sales 2023 * 270M 294M Sales 2024 * 281M 306M Capitalization 91.48M 99.67M
Net income 2023 * 7M 7.63M Net income 2024 * 9M 9.81M EV / Sales 2023 * 0.26 x
Net cash position 2023 * 21.3M 23.21M Net cash position 2024 * 24.3M 26.48M EV / Sales 2024 * 0.24 x
P/E ratio 2023 *
-
P/E ratio 2024 *
-
Employees 76
Yield 2023 *
-
Yield 2024 *
-
Free-Float 99.67%
More Fundamentals * Assessed data
Dynamic Chart
1 day-5.41%
1 week-1.13%
Current month-4.37%
1 month+0.57%
3 months-11.62%
More quotes
1 week
17.10
Extreme 17.1
18.75
1 month
16.00
Extreme 16
18.75
Current year
15.00
Extreme 15
20.80
1 year
15.00
Extreme 15
20.80
3 years
15.00
Extreme 15
20.80
5 years
15.00
Extreme 15
20.80
10 years
15.00
Extreme 15
20.80
More quotes
Date Price Change Volume
24-06-06 17.5 -5.41% 5,017
24-06-05 18.5 0.00% 420
24-06-04 18.5 -1.33% 470
24-06-03 18.75 +2.46% 1,347
24-05-31 18.3 +3.39% 682

End-of-day quote Hanseatische Wertpapierboerse Hamburg, June 05, 2024

More quotes
Haemato AG, previously Windsor AG, is a Germany-based pharmaceutical company. The Company trades and patent-free and patent-protected medicines and generic drugs with focus on oncology, human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS), neurology, rheumatology, urology, cardiovascular diseases and other chronic diseases. The Company's main markets are Europe, North America and Japan. It also imports medicines from within the European Economic Area in form of parallel imports and re-imports. The Company's subsidiaries are Haemato Pharm GmbH, Heamato Med GmbH, Castell Pharma BV, Sanate GmbH and Heamato Asia Co Ltd. Customers can order medicine through phone, fax and e-mail, among others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Quarterly revenue - Rate of surprise